bpc-157 hcl vs arg as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers Bpc-157 Arg + Kpv Blend
Description
P., Lynn, P., Costa, M
I would say 90% have ended up with pretty intense GI problems from it
For example, a large molecular weight sugar such as mannitol cannot cross cell membranes and it will be distributed in ECF but not in ICF
With semaglutide and tirzepatide, many people experience nausea, diarrhea, constipation, heartburn and other gastrointestinal side effects
